详情页

当前位置：首页 > 详情页

The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy (vol 13, 1167625, 2023)

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Hebei Med Univ, Hosp 4, Dept Radiat Oncol, Shijiazhuang, Peoples R China [2]Hebei Normal Univ, Coll Life Sci, Hebei Key Lab Anim Physiol Biochem & Mol Biol, Shijiazhuang, Peoples R China

出处：

DOI：

ISSN：

关键词： esophageal squamous cell carcinoma second-line treatment immune checkpoint inhibitors controlling nutritional status systemic inflammation score prognosis

语种：

WOS：

PubmedID：

中科院分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2025]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2023]版：

Q2 ONCOLOGY

最新[2024]版：

Q2 ONCOLOGY

影响因子： 3.3 最新[2024版] 3.8 最新五年平均 3.5 出版当年[2023版] 4 出版当年五年平均 4.7 出版前一年[2022版] 3.3 出版后一年[2024版]

第一作者：

第一作者机构： [1]Hebei Med Univ, Hosp 4, Dept Radiat Oncol, Shijiazhuang, Peoples R China

通讯作者：

通讯机构： [1]Hebei Med Univ, Hosp 4, Dept Radiat Oncol, Shijiazhuang, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The prognosis value of CONUT and SIS score for recurrent or metastatic esophageal squamous cell carcinoma patients treated with second-line immunotherapy [2]Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma. [3]Novel nomograms predicting the survival of patients with nonsurgical thoracic esophageal squamous cell carcinoma treated with IMRT: A retrospective analysis [4]A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma [5]Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma [6]Correlation between immune-related adverse events and treatment efficacy of anti-PD1 immunotherapy in patients with esophageal squamous cell carcinoma [7]免疫联合方案二线治疗食管鳞癌患者的初步分析 [8]Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma. [9]Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm phase II study [10]The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma